News

Results of the Alcon Eye on Cataract Survey highlight misconceptions about cataract surgery, revealing the need to educate the 50+ population on the procedure and treatment options.

Researchers are involved in the development of Eye2Gene, an AI system capable of identifying the genetic cause of IRDs from retinal scans.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

A vitreoretinal surgeon, Hariprasad joined the University of Chicago in 2005, and has been serving as interim chairman since 2020.

Scientists hope to develop of novel AI solutions for the prediction of DPN using corneal OCT images.

SBI-100 is a cannabinoid receptor type 1 (CB1R) agonist administered topically onto the eye to reduce IOP and treat glaucoma.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

EverPatch is described by the company as the world's first non-degradable, synthetic tissue substitute for ophthalmic surgery.

OTX-TKI is Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

RAFARM and BioNanoSim have entered into an agreement to create the company.

Elaine Ye Wang, MD, discusses the MicroPulse TLT and the benefits the procedure because it does not require patients to alter their lifestyle.

Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.

According to the company, CyclASol is preservative-free and does not contain any oils or surfactants, which can be irritating and disturbing for the tear film.

The Texas Medical Board suspends the license of David Stager Jr, MD, FACS, FAAP, a year after he had complied with a previous disciplinary action.

The topical drug is being tested in a multi-center, double-masked, placebo-controlled trial to treat dry eye disease (DED).

The $150 Million Series B funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.

NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

Elaine Ye Wang, MD, discusses adapting transscleral laser therapy (TLT) using MicroPulse technology into her practice and the benefits of using the technique.

According to researchers, lesions in women’s eyes were significantly more likely to occur in the central retina compared with those in men’s eyes.

The ophthalmic solution from VivaVision is being studied for the treatment of glaucoma.

An inexpensive laser could increase access to OCT imaging, helping to catch eye problems early.

Doheny Eye Institute announced Ghosh was recognized by Research to Prevent Blindness and the International Retinal Research Foundation.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Alice Epitropoulos, MD, goes over meibomian gland dysfunction and the most common reasons it is missed in diagnosis and how to avoid them.

For Michael A. Puente Jr., MD, being open about himself and advocating for an overlooked community hasn’t always been as easy as it is today. Progress has been incremental, but he is optimistic about the state of ophthalmology for LGBTQ+ physicians and patients.

The event is a forum for the exchange of ideas between leading scientists in diverse fields to bring their knowledge to the challenges of glaucoma and help set the course for future glaucoma research.

Surgeons from iLink Centers of Excellence offer pearls, from optimal scheduling to networking.